<DOC>
	<DOC>NCT00643500</DOC>
	<brief_summary>Patients with partial-onset seizures seen in community-based practices were to be included in this therapeutic use study - to assess the safety and tolerability of Keppra (Levetiracetam) and to confirm the favorable safety of the drug found during clinical development - to obtain further information about optimal dosing in daily clinical practice. Compared to previous registration trials, the study population corresponded more closely to that seen in daily clinical practice.</brief_summary>
	<brief_title>Pharmacovigilance Study of Keppra. SPAIN - SKATE : Safety of Keppra as Adjunctive Therapy in Epilepsy</brief_title>
	<detailed_description />
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Epilepsies, Partial</mesh_term>
	<mesh_term>Etiracetam</mesh_term>
	<criteria>Male and female older than 16 years; Epilepsy with partial onset seizures, with or without secondary generalization; At least one concomitant marketed antiepileptic drug Safety reasons</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Levetiracetam</keyword>
	<keyword>Keppra</keyword>
</DOC>